Marker Therapeutics (MRKR) Price & Analysis

Compare

560 Followers

MRKR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.81 - $5.95

Previous CloseN/A

Volume39.59K

Average Volume (3M)1.89M

Market Cap

$11.99M

Enterprise Value$9.54M

Total Cash (Recent Filing)$10.46M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.02

Next Earnings

Nov 06, 2025

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding12,938,910

10 Day Avg. Volume268,599

30 Day Avg. Volume1,891,886

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.80

Enterprise Value/Revenue1.77

Enterprise Value/Gross Profit-2.37

Enterprise Value/Ebitda-1.14

Forecast

1Y Price Target

$8.00

Price Target Upside779.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAnalyst maintains a BUY rating and $8 price target on Marker based on the expectation for continued positive clinical data for MT-601.

Market OpportunityMarker estimates a market opportunity of approximately $1.7B for relapsed lymphoma patients after CAR-T therapy.

Bears Say

Regulatory ChallengesAnalyst anticipates updated MT-601 Phase 1 APOLLO data, including more patients, followed by a pivotal trial discussion with FDA.

Marker Therapeutics News

Marker Therapeutics Reports Promising Phase 1 Study Results

Marker Therapeutics ( ($MRKR) ) just unveiled an announcement. On August 26, 2025, Marker Therapeutics announced encouraging results...

1M ago

MRKR

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

Marker Therapeutics (MRKR) provided an update on the progress and clinical observations from the Phase 1 APOLLO study....

1M ago

MRKR

Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline

Marker Therapeutics ( ($MRKR) ) has released its Q2 earnings. Here is a breakdown of the information Marker...

2M ago

MRKR

Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics, with...

2M ago

MRKR

Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR...

4M ago

MRKR

Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing

Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 16, 2025, Marker Therapeutics entered into a...

4M ago

MRKR

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Marker Therapeutics (MRKR) announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization,...

4M ago

MRKR

Marker Therapeutics Concludes Annual Stockholders Meeting

Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 6, 2025, Marker Therapeutics held its Annual...

4M ago

MRKR

Marker Therapeutics Reports Q1 2025 Financial Results

Marker Therapeutics ( ($MRKR) ) has released its Q1 earnings. Here is a breakdown of the information Marker...

4M ago

MRKR

Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR...

4M ago

MRKR

Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells

The latest update is out from Marker Therapeutics ( ($MRKR) ). Marker Therapeutics has reported that lymphodepletion enhances...

4M ago

MRKR

Marker Therapeutics reports evidence from Phase 1 APOLLO study

Marker Therapeutics (MRKR) reported scientific evidence from the Phase 1 APOLLO study demonstrating that lymphodepletion improves the expansion...

5M ago

MRKR

Marker Therapeutics Advances T Cell Therapies in 2024

Marker Therapeutics ( ($MRKR) ) has released its Q4 earnings. Here is a breakdown of the information Marker...

5M ago

MRKR

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

Reports FY24 revenue $6.59M, consensus $8.32M. “In 2024, we made substantial progress advancing MT-601, our lead multi antigen...

6M ago

MRKR

MRKR FAQ

What was Marker Therapeutics Inc’s price range in the past 12 months?

Marker Therapeutics Inc lowest stock price was $0.81 and its highest was $5.95 in the past 12 months.

What is Marker Therapeutics Inc’s market cap?

Marker Therapeutics Inc’s market cap is $11.99M.

When is Marker Therapeutics Inc’s upcoming earnings report date?

Marker Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 35 days.

How were Marker Therapeutics Inc’s earnings last quarter?

Marker Therapeutics Inc released its earnings results on Aug 18, 2025. The company reported -$0.249 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.055.

Is Marker Therapeutics Inc overvalued?

According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marker Therapeutics Inc pay dividends?

Marker Therapeutics Inc does not currently pay dividends.

What is Marker Therapeutics Inc’s EPS estimate?

Marker Therapeutics Inc’s EPS estimate is -0.36.

How many shares outstanding does Marker Therapeutics Inc have?

Marker Therapeutics Inc has 12,938,910 shares outstanding.

What happened to Marker Therapeutics Inc’s price movement after its last earnings report?

Marker Therapeutics Inc reported an EPS of -$0.249 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went down -3.968%.

Which hedge fund is a major shareholder of Marker Therapeutics Inc?

Currently, no hedge funds are holding shares in MRKR

Marker Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-144.68%

Trailing 12-Months

Asset Growth

26.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Marker Therapeutics Inc

Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company specializing in the development of innovative cell therapies for the treatment of hematological malignancies and solid tumors. The company's proprietary technology, MultiTAA-specific T cell therapy, is designed to selectively target tumor-associated antigens, offering a potentially more effective and safer alternative to conventional cancer treatments. Marker Therapeutics is focused on advancing its lead product candidates through clinical trials to address unmet medical needs in cancer care.

Marker Therapeutics (MRKR) Earnings & Revenues

Historic Earnings Reports

MRKR Stock 12 Month Forecast

Average Price Target

$8.00

▲(779.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8615384615384616,2.3730769230769235,2.884615384615385,3.3961538461538465,3.907692307692308,4.41923076923077,4.930769230769231,5.442307692307693,5.953846153846154,6.465384615384616,6.976923076923077,7.488461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8615384615384616,2.3730769230769235,2.884615384615385,3.3961538461538465,3.907692307692308,4.41923076923077,4.930769230769231,5.442307692307693,5.953846153846154,6.465384615384616,6.976923076923077,7.488461538461539,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8615384615384616,2.3730769230769235,2.884615384615385,3.3961538461538465,3.907692307692308,4.41923076923077,4.930769230769231,5.442307692307693,5.953846153846154,6.465384615384616,6.976923076923077,7.488461538461539,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.35,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.64,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >